Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review

Published:2022-07-07 Issue:2 Volume:199 Page:190-204
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

McCaughan Georgia J.¹²^ORCID,Gandolfi Sara³⁴,Moore John J.¹²,Richardson Paul G.⁵

Affiliation:

1. Department of Haematology St Vincent's Hospital Sydney Australia

2. University of New South Wales, Medicine and Health Sydney Australia

3. Translational Research Program University of Helsinki Helsinki Finland

4. Haematology Research Unit University of Helsinki and Helsinki University Hospital Helsinki Finland

5. Dana‐Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology Boston Massachusetts USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18295

Reference102 articles.

1. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

2. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

3. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

4. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

5. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognosis of concurrent renal impairment at diagnosis of multiple myeloma: a systematic review;Annals of Medicine;2024-07-22

2. Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy;Cell Communication and Signaling;2024-06-11

3. Identification and validation of a platelet-related signature for predicting survival and drug sensitivity in multiple myeloma;Frontiers in Pharmacology;2024-05-16

4. Mitigating time toxicity in lymphoma and multiple myeloma;Leukemia & Lymphoma;2024-05-15

5. Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis;Blood Cancer Journal;2024-03-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3